US pharmaceutical companies Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) and Moderna Inc. (NASDAQ: MRNA) have initiated the Phase III INTerpath-009 study to evaluate V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). The study will focus on patients with resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC) who did not achieve a pathological complete response (pCR) after neoadjuvant treatment with KEYTRUDA plus platinum-based chemotherapy. The global enrollment for the INTerpath-009 study has begun, with the first patients enrolled in Canada.
mRNA-4157 (V940) is a novel mRNA-based individualized neoantigen therapy that includes a synthetic mRNA coding for up to 34 neoantigens, designed according to the unique mutational signature of the patient’s tumor DNA sequence. The combination therapy of V940 and Keytruda is also under assessment in other cancer types, including melanoma (INTerpath-001, NCT05933577), NSCLC (INTerpath-002, NCT06077760), squamous cell carcinoma of the skin (INTerpath-007, NCT06295809), renal cell carcinoma (INTerpath-004, NCT06307431), and urothelial carcinoma (INTerpath-005, NCT06305767).- Flcube.com
